0HLK Stock Overview
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Krka, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €126.00 |
| 52 Week High | €126.00 |
| 52 Week Low | €108.50 |
| Beta | 0.50 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 82.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HLK | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 5.0% | 1.4% |
| 1Y | n/a | 5.0% | 1.1% |
Return vs Industry: Insufficient data to determine how 0HLK performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0HLK performed against the UK Market.
Price Volatility
| 0HLK volatility | |
|---|---|
| 0HLK Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0HLK has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0HLK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 10,284 | Jože Colaric | www.krka.si |
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular, alimentary tract and metabolism, central nervous system, infections, oncology, and other diseases. The company also provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others.
Krka, d. d. Fundamentals Summary
| 0HLK fundamental statistics | |
|---|---|
| Market cap | €3.87b |
| Earnings (TTM) | €313.95m |
| Revenue (TTM) | €1.81b |
12.3x
P/E Ratio2.1x
P/S RatioIs 0HLK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HLK income statement (TTM) | |
|---|---|
| Revenue | €1.81b |
| Cost of Revenue | €779.68m |
| Gross Profit | €1.03b |
| Other Expenses | €712.76m |
| Earnings | €313.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | 10.18 |
| Gross Margin | 56.84% |
| Net Profit Margin | 17.38% |
| Debt/Equity Ratio | 0% |
How did 0HLK perform over the long term?
See historical performance and comparison